106 related articles for article (PubMed ID: 8858390)
1. Self-injection devices for intracavernosal pharmacotherapy: operational classification and safety considerations.
Pescatori ES; Calpista A; Artibani W; Pagano F; Calabro A
Int J Impot Res; 1996 Jun; 8(2):53-7; discussion 57-8. PubMed ID: 8858390
[TBL] [Abstract][Full Text] [Related]
2. Comparison of long-term outcomes of penile prostheses and intracavernosal injection therapy.
Sexton WJ; Benedict JF; Jarow JP
J Urol; 1998 Mar; 159(3):811-5. PubMed ID: 9474156
[TBL] [Abstract][Full Text] [Related]
3. Comparison of a needle-free high-pressure injection system with needle-tipped injection of intracavernosal alprostadil for erectile dysfunction.
Harding LM; Adeniyi A; Everson R; Barker S; Ralph DJ; Baranowski AP
Int J Impot Res; 2002 Dec; 14(6):498-501. PubMed ID: 12494285
[TBL] [Abstract][Full Text] [Related]
4. Intracavernosal prostaglandin E1 self vs office injection therapy in patients with erectile dysfunction.
El-Sakka AI
Int J Impot Res; 2006; 18(2):180-5. PubMed ID: 16163370
[TBL] [Abstract][Full Text] [Related]
5. Multiple retained needles: an unusual complication of intracavernous self-injection.
Bandi G; Rajpurkar A; MacDonald MF; Dhabuwala CB
Urology; 2005 Apr; 65(4):797. PubMed ID: 15833537
[TBL] [Abstract][Full Text] [Related]
6. Clinical course of penile fibrosis in intracavernosal prostaglandin E1 injection therapy: a follow-up of 44 patients.
Chew KK; Stuckey BG
Int J Impot Res; 2003 Apr; 15(2):94-8. PubMed ID: 12789387
[TBL] [Abstract][Full Text] [Related]
7. The treatment of loss of penile rigidity associated with Peyronie's disease.
Krane RJ
Scand J Urol Nephrol Suppl; 1996; 179():147-50. PubMed ID: 8908682
[TBL] [Abstract][Full Text] [Related]
8. The causes of patient dropout from penile self-injection therapy for impotence.
Mulhall JP; Jahoda AE; Cairney M; Goldstein B; Leitzes R; Woods J; Payton T; Krane RJ; Goldstein I
J Urol; 1999 Oct; 162(4):1291-4. PubMed ID: 10492182
[TBL] [Abstract][Full Text] [Related]
9. The additive erectile recovery effect of brain-derived neurotrophic factor combined with vascular endothelial growth factor in a rat model of neurogenic impotence.
Chen KC; Minor TX; Rahman NU; Ho HC; Nunes L; Lue TF
BJU Int; 2005 May; 95(7):1077-80. PubMed ID: 15839936
[TBL] [Abstract][Full Text] [Related]
10. Intracavernosal adrenalin injection in priapism.
Keskin D; Cal C; Delibaş M; Ozyurt C; Günaydin G; Nazli O; Cüreklibatir I
Int J Impot Res; 2000 Dec; 12(6):312-4. PubMed ID: 11416834
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of 452 patients with erectile dysfunction treated by combinations of vasoactive agents by penile injection].
Segenreich E; Israilov S; Shmueli J; Simon D; Baniel J; Livne P
Harefuah; 1998 May; 134(9):673-8, 750. PubMed ID: 10909609
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a no-needle penile injector: a preliminary study evaluating tissue penetration and its hemodynamic consequences in the rat.
Seyam RM; Bégin LR; Tu LM; Dion SB; Merlin SL; Brock GB
Urology; 1997 Dec; 50(6):994-8. PubMed ID: 9426740
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction.
Perimenis P; Konstantinopoulos A; Perimeni PP; Gyftopoulos K; Kartsanis G; Liatsikos E; Athanasopoulos A
Asian J Androl; 2006 Mar; 8(2):219-24. PubMed ID: 16491275
[TBL] [Abstract][Full Text] [Related]
14. Evaluating erectile dysfunction: oral sildenafil versus intracavernosal injection of papaverine.
Viswaroop B; B A; Gopalakrishnan G
Natl Med J India; 2005; 18(6):299-301. PubMed ID: 16483029
[TBL] [Abstract][Full Text] [Related]
15. [The impact of creating andrology units on the treatment of erectile dysfunction with intracavernosal injections].
Ramada Benlloch FJ; Navalon Verdejo P; Claramonte Ramon FJ; Beltrán Mesenguer JF; Ramos de Campos M; Zaragozá Orts J
Arch Esp Urol; 1999 Apr; 52(3):257-61. PubMed ID: 10371742
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of erectile response and cAMP accumulation by combination of prostaglandin E1 and rolipram, a selective inhibitor of the type 4 phosphodiesterase (PDE 4).
Bivalacqua TJ; Champion HC; Rajasekaran M; Sikka SC; Kadowitz PJ; Doherty PC; Hellstrom WJ
J Urol; 1999 Nov; 162(5):1848-55. PubMed ID: 10524946
[TBL] [Abstract][Full Text] [Related]
17. Intracavernosal injection therapy: a practical guide.
Mulhall JP
Tech Urol; 1997; 3(3):129-34. PubMed ID: 9422443
[TBL] [Abstract][Full Text] [Related]
18. MUSE therapy: preliminary clinical observations.
Werthman P; Rajfer J
Urology; 1997 Nov; 50(5):809-11. PubMed ID: 9372900
[TBL] [Abstract][Full Text] [Related]
19. Erectile dysfunction: anatomical parameters, etiology, diagnosis, and therapy.
Hafez ES; Hafez SD
Arch Androl; 2005; 51(1):15-31. PubMed ID: 15764414
[TBL] [Abstract][Full Text] [Related]
20. Current status of local penile therapy.
Montorsi F; Salonia A; Zanoni M; Pompa P; Cestari A; Guazzoni G; Barbieri L; Rigatti P
Int J Impot Res; 2002 Feb; 14 Suppl 1():S70-81. PubMed ID: 11850739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
